
Victoza® demonstrated CV risk reduction in the LEADER trial¹

Topline results¹



Victoza® demonstrated superiority with a significant reduction in cardiovascular (CV) risk



The safety profile of Victoza® in LEADER was consistent with previous liraglutide trials

LEADER facts¹

LEADER investigated the CV safety of Victoza® in adults with type 2 diabetes and high CV risk



410 trial sites



3Z countries



3.5-5 years

Reference:

1.Marso SP, et al; Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. June 13, 2016.



